ReviewPathogens (Basel, Switzerland)2020
Porcine Circovirus 2 Genotypes, Immunity and Vaccines: Multiple Genotypes but One Single Serotype.
Review in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 82 citations in OpenAlex.
- Molecular Variation in Porcine Circovirus Type 2 in Jalisco, Mexico, and Its Potential Impact on Vaccine Efficacy.Vaccines · 2026Article
- Outbred mice as an appropriate model for evaluating the immunogenicity of vaccines against porcine circovirus 2.Open veterinary journal · 2026Article
- Molecular Detection and Phylogenetic Analysis of Selected Viral Pathogens in Wild Boar Populations of Russia.Viruses · 2026Article
- Development of Magnetic Particle-Based Chemiluminescence Immunoassays for Detecting PCV2 VLP- and Rep-Specific Antibodies and Their Combined Use for Immune Evaluation and Replication-Associated Exposure Assessment.Transboundary and emerging diseases · 2026Article
- Virus-like Particles Carrying a Porcine Circovirus Type 2b Peptide Induce an Antibody Response and Reduce Viral Load in Immunized Pigs.Vaccines · 2025Article
- Knowledge gaps in research and control of porcine circovirus 2 (PCV2) infections.BMC veterinary research · 2025Review
- Efficacy of a new ready-to-use PCV2 andVeterinarni medicina · 2025Article
- Speculative Review on the Feasibility of Porcine Circovirus 2 Elimination.Animals : an open access journal from MDPI · 2025Review
- Article
- PCV2 Infection Upregulates SOCS3 Expression to Facilitate Viral Replication in PK-15 Cells.Viruses · 2025Article
- Longitudinal Monitoring of Mono- and Coinfections Involving Primary Porcine Reproductive Viruses (PCV2, PPV1, and PRRSV) as Well as Emerging Viruses (PCV3, PCV4, and nPPVs) in Primiparous and Multiparous Sows and Their Litters.Pathogens (Basel, Switzerland) · 2025Article
- Efficacy of a new ready-to-use vaccine against PCV-2d andVeterinarni medicina · 2025Article
- Cellular immune signatures and differences of four porcine circovirus type 2 vaccines to heterologous PCV2d infection.NPJ vaccines · 2025Article
- Epidemiological and genetic variation analysis of emerging porcine circovirus type 2 in Henan Province, 2023.Frontiers in veterinary science · 2025Article
- Comparative Pathogenicity of PCV2, PCV3, and PCV4 in Piglets: Insights Into Clinical, Pathological, and Immunological Features.Transboundary and emerging diseases · 2025Article
- Host-driven evolution of PCV2: insights into genetic diversity and adaptation.Frontiers in immunology · 2025Article
- Sow reproductive disorders: a key issue affecting the pig industry.Frontiers in veterinary science · 2025Review
- Assessment of PRRSV and PCV2 seroprevalence and antigen prevalence in minipigs at laboratory-animal production facilities.Journal of advanced veterinary and animal research · 2024Article
- Molecular Positivity of Porcine Circovirus Type 2 Associated with Production Practices on Farms in Jalisco, Mexico.Viruses · 2024Article
- Frequency and Genetic Analysis of Porcine Circovirus Type 2, Which Circulated between 2014 and 2021 in Jiangsu, China.Animals : an open access journal from MDPI · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identified for the first time in the 1990s, Porcine circovirus 2 (PCV-2) should not be considered an emerging virus anymore. Nevertheless, many aspects of its biology and epidemiology are still controversial. Particularly, its high evolutionary rate has caused the emergence of several variants and genotypes, alternating on the worldwide proscenium. The biological and practical implications of such heterogenicity are unfortunately largely unknown. The effectiveness of currently available vaccines against new genotypes that have emerged over time has been the topic of an intense debate and often inconclusive or contradictory results between experimental, field, and epidemiological studies have been gathered. The challenge in establishing an effective PCV-2 disease model, the peculiarities in experimental design and settings and the strains involved could justify the observed differences. The present work aims to summarize and critically review the available knowledge on PCV-2 genetic heterogeneity, immunity, and vaccine efficacy, organizing and harmonizing the available data from different sources, shedding light on this complex field and highlighting current knowledge gaps and future perspectives. So far, all vaccines in the market have shown great efficacy in reducing clinical signs associated to diseases caused by PCV-2, independently of the genotype present in the farm. Moreover, experimental data demonstrated the cross-protection of PCV-2a vaccines against the most widespread genotypes (PCV-2a, PCV-2b, and PCV-2d). Therefore, despite the significant number of genotypes described/proposed (PCV-2a to PCV-2i), it seems one single PCV-2 serotype would exist so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.